These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23437952)

  • 1. Estimating covariate-adjusted log hazard ratios in randomized clinical trials using cox proportional hazards models and nonparametric randomization based analysis of covariance.
    Saville BR; Koch GG
    J Biopharm Stat; 2013 Mar; 23(2):477-90. PubMed ID: 23437952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonparametric randomization-based covariate adjustment for stratified analysis of time-to-event or dichotomous outcomes.
    Hussey MA; Koch GG; Preisser JS; Saville BR
    J Biopharm Stat; 2016; 26(3):579-89. PubMed ID: 26101805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonparametric covariate adjustment in estimating hazard ratios.
    Jiang H; Kulkarni PM; Wang Y; Mallinckrodt CH
    Pharm Stat; 2016; 15(1):46-53. PubMed ID: 26610282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary nonparametric analysis of covariance for logistic regression in a randomized clinical trial setting.
    Tangen CM; Koch GG
    J Biopharm Stat; 1999 Mar; 9(1):45-66. PubMed ID: 10091909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.
    Tangen CM; Koch GG
    J Biopharm Stat; 1999 May; 9(2):307-38. PubMed ID: 10379696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomization-based adjustment of multiple treatment hazard ratios for covariates with missing data.
    Lam D; Koch GG; Preisser JS; Saville BR; Hussey MA
    J Biopharm Stat; 2017; 27(3):373-386. PubMed ID: 28281895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.
    Zhao Y; Saville BR; Zhou H; Koch GG
    J Biopharm Stat; 2016; 26(2):269-79. PubMed ID: 25635808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cox regression methods for two-stage randomization designs.
    Lokhnygina Y; Helterbrand JD
    Biometrics; 2007 Jun; 63(2):422-8. PubMed ID: 17425633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualizing covariates in proportional hazards model.
    Karvanen J; Harrell FE
    Stat Med; 2009 Jun; 28(14):1957-66. PubMed ID: 19378282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis methodology for combining treatment effects from Cox proportional hazard models with different covariate adjustments.
    Yuan X; Anderson SJ
    Biom J; 2010 Aug; 52(4):519-37. PubMed ID: 20661952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
    Karrison T; Kocherginsky M
    Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-parametric covariance methods for incidence density analyses of time-to-event data from a randomized clinical trial and their complementary roles to proportional hazards regression.
    Tangen CM; Koch GG
    Stat Med; 2000 Apr; 19(8):1039-58. PubMed ID: 10790679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-component mixture cure rate model with spline estimated nonparametric components.
    Wang L; Du P; Liang H
    Biometrics; 2012 Sep; 68(3):726-35. PubMed ID: 22169032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-parametric estimation for baseline hazards function and covariate effects with time-dependent covariates.
    Gao F; Manatunga AK; Chen S
    Stat Med; 2007 Feb; 26(4):857-68. PubMed ID: 16685705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dealing with competing risks: testing covariates and calculating sample size.
    Pintilie M
    Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
    Baker SG; Fitzmaurice GM; Freedman LS; Kramer BS
    Biostatistics; 2006 Jan; 7(1):29-40. PubMed ID: 15923407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data.
    Halpin DM; Peterson S; Larsson TP; Calverley PM
    Respir Med; 2008 Nov; 102(11):1615-24. PubMed ID: 18691861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permutation test following covariate-adaptive randomization in randomized controlled trials.
    Hasegawa T; Tango T
    J Biopharm Stat; 2009; 19(1):106-19. PubMed ID: 19127470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.